In 156 patients with advanced melanoma, adding the telomerase vaccine UV1 to ipilimumab-nivolumab did not improve PFS (projected median 34.3 vs 38.4 months; HR 0.95); response rates (59.7% vs 59.2%) and grade >3 adverse events were similar.
RCTn = 156
Lorigan et al. The telomerase vaccine UV1 combined with ipilimumab and nivolumab versus ipilimumab and nivolumab in advanced melanoma (INITIUM): A randomized open-label phase 2 study